Why the study?
How does the transition from argatroban to vitamin K antagonists affect coagulation monitoring assays in healthy volunteers?
How does the transition from argatroban to vitamin K antagonists affect coagulation monitoring assays in healthy volunteers?
During transition from argatroban to VKA, an INR of 4.0 can be used as a safe threshold for discontinuing argatroban (up to 2 microg/kg/min), and ECT can reliably monitor argatroban without VKA interference.
Authors
No takes yet. Share an insight, caveat, or question.
May support INR 4.0 threshold for argatroban discontinuation on VKA overlap; leaves open prospective validation in patients.
Graff et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: